HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N-acetylated-alpha-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia.

Abstract
Excessive glutamate receptor activation is thought to be involved in the retinal ganglion cell (RGC) death after ischemic injury. In this study, we examined the effect of 2-PMPA (2-(phosphonomethyl)pentanedioic acid) on RGC survival in an ischemia-reperfusion model using C57BL/6 mouse eyes. 2-PMPA is a NAALADase (N-acetylated-alpha-linked-acidic dipeptidase) inhibitor, an enzyme responsible for the hydrolysis of the neuropeptide NAAG (N-acetyl-aspartyl-glutamate) to N-acetyl-aspartate and glutamate. 100mg/kg 2-PMPA were given with intraperitoneal injections 30 min before ischemia followed per hour injection for 3h. 2-PMPA increased surviving RGCs as well as retinal thickness after pressure-induced retinal ischemia. In addition, neuroprotection afforded by 2-PMPA was greater than that of N-methyl-D-aspartate receptor blocker. These data indicate that NAALADase inhibition may be useful in retinal disorders in which excessive amino acid transmission is pathogenic.
AuthorsC Harada, T Harada, B S Slusher, K Yoshida, H Matsuda, K Wada
JournalNeuroscience letters (Neurosci Lett) Vol. 292 Issue 2 Pg. 134-6 (Oct 06 2000) ISSN: 0304-3940 [Print] Ireland
PMID10998567 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-(phosphonomethyl)pentanedioic acid
  • Neuroprotective Agents
  • Organophosphorus Compounds
  • Carboxypeptidases
  • Glutamate Carboxypeptidase II
Topics
  • Animals
  • Carboxypeptidases (antagonists & inhibitors, metabolism)
  • Glutamate Carboxypeptidase II
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents (pharmacology)
  • Optic Neuropathy, Ischemic (drug therapy, metabolism)
  • Organophosphorus Compounds (pharmacology)
  • Pressure
  • Reperfusion Injury (drug therapy, metabolism)
  • Retinal Ganglion Cells (enzymology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: